Research News
The FDA has approved the use of atypical antipsychotic drug Rexulti (brexpiprazole) for treating agitation associated with Alzheimer’s dementia, making it the first FDA-approved treatment for Alzheimer’s agitation in the U.S.
A BrightFocus-funded research team has some eye-opening news: They’ve used artificial intelligence to develop a model that could one day detect Alzheimer’s disease through photographs of the eye, which could lead to earlier diagnosis and treatment.
Researchers have identified a new gene region in people of African descent that reduces Alzheimer's disease risk—highlighting the importance of diversity and inclusion of all populations in research.
A BrightFocus Foundation-funded study found that even moderate alcohol use can cause changes in the brain that may accelerate Alzheimer’s disease, shedding new light on a possible modifiable risk factor for dementia.
BrightFocus-funded research offers new evidence of the importance of tau in the prediction of Alzheimer’s disease which could lead to ways to delay—or even stop—the disease from progressing.
Led by a BrightFocus grantee, a research team has developed a new marker of Alzheimer’s disease neurodegeneration in the blood, paving the way for a more accurate blood test to detect Alzheimer’s disease.
Using a molecule found in green tea, an Alzheimer's Disease Research-funded team of biochemists has identified new molecules that can destroy protein tangles in the brain linked to Alzheimer's and related brain diseases.
A new BrightFocus-funded clinical trial is one of the first to study the benefits of exercise in protecting brain health specifically among older African Americans.
A new blood test that could facilitate a more accurate diagnosis of Alzheimer’s during the initial phases of the disease is on the way—rooted in critical early support from Alzheimer’s Disease Research, a program of BrightFocus Foundation. Catching the disease as soon as possible offers affected individuals the greatest gift of all—more time to spend with loved ones and explore disease management and treatment options.
Clinical trial results released Nov. 29 for lecanemab, a drug targeting early Alzheimer’s disease, reported a moderate slowing of cognitive decline in patients by 25% through the removal of amyloid-beta (Aβ) in the brain.